Dr. Pinato on Study of Immune-Tolerogenic Pathways in Primary and Metastatic HCC

David James Pinato, MD, MRCP, PhD
Published: Friday, Apr 21, 2017



David James Pinato, MD, MRCP, PhD, Faculty of Medicine, Department of Surgery and Cancer, NIHR Academic Clinical Lecturer, Imperial College London, discusses a study of intratumor heterogeneity in the regulation of immune-tolerogenic pathways in primary and metastatic hepatocellular carcinoma (HCC).

Recent biomarker studies have shown that PD-1/PD-L1 targeted therapies are an efficacious systemic treatment for patients with HCC, says Pinato. PD-1 is already used as a biomarker in clinical trials, but trials in solid tumors suggest heterogeneity in PD-L1 expression in the primary metastatic population as well.

Based on this, a study was conducted to analyze PD-L1 and PD-L2 expression by immunohistochemistry. Pinato says the findings of this study may have implications for how patients are selected for immunotherapy, but that needs further research.
 

<<< View more from the 2017 International Liver Congress



David James Pinato, MD, MRCP, PhD, Faculty of Medicine, Department of Surgery and Cancer, NIHR Academic Clinical Lecturer, Imperial College London, discusses a study of intratumor heterogeneity in the regulation of immune-tolerogenic pathways in primary and metastatic hepatocellular carcinoma (HCC).

Recent biomarker studies have shown that PD-1/PD-L1 targeted therapies are an efficacious systemic treatment for patients with HCC, says Pinato. PD-1 is already used as a biomarker in clinical trials, but trials in solid tumors suggest heterogeneity in PD-L1 expression in the primary metastatic population as well.

Based on this, a study was conducted to analyze PD-L1 and PD-L2 expression by immunohistochemistry. Pinato says the findings of this study may have implications for how patients are selected for immunotherapy, but that needs further research.
 

<<< View more from the 2017 International Liver Congress


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x